CombiMatrix Announces Multicycle Offering for Pre-Implantation Genetic Screening and Improved Cost Efficiencies
16 Diciembre 2015 - 5:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for prenatal,
miscarriage analysis, postnatal developmental disorders, and
pre-implantation genetic screening (PGS) services, today announced
that it has launched its PGS Multicycle Program. The PGS Multicycle
Program provides patients the flexibility of testing eight embryos
over the course of 12 months for a one-time payment.
CombiMatrix is the pioneer in per-embryo pricing in conjunction
with PGS testing. With the addition of a multicycle PGS
option, CombiMatrix continues to offer the most flexible,
cost-effective solutions for patients while increasing the upfront
cash payments received for genetic testing services.
“By offering the PGS Multicycle Program, we are
making PGS more cost effective for physicians and their patients.
We are delighted to provide an additional option to our existing
flexible ‘per embryo’ pricing structure, where patients pay only
for those embryos being tested,” said Mark McDonough, President and
Chief Executive Officer of CombiMatrix. “In leveraging our
commercial expertise and offering disruptive solutions such as the
only nationwide PGS testing program with built-in shipping cost for
transparency, we are further strengthening our position in this
growing market.”
“Additionally, we have implemented PGS shipping
process improvements, resulting in increased convenience to
physicians and embryologists, as well as providing significant cost
reductions. This gives us operating leverage and allows us to
pass further savings onto IVF clinics and their patients,”
McDonough added.
CombiMatrix employs innovative ways to provide
unique, value-added options to its offerings, such as:
- No separate charge for embryo batching
- Pre-labeled barcode scanning for extra embryo security and
tracking
- Biopsy services utilizing CombiMatrix embryologist and
equipment (laser provided)
- Free access to the company’s embryologist for PGS
customers
- Easy-to-use online provider portal to view status reports
“Our continued focus on our customers and their
patients is evident in the high-tech, high-touch approach to our
service offerings,” concluded McDonough.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic screening, miscarriage
analysis, prenatal and pediatric diagnostics, offering DNA-based
testing for the detection of genetic abnormalities beyond what can
be identified through traditional methodologies. CombiMatrix
performs genetic testing utilizing a variety of advanced
cytogenomic techniques, including chromosomal microarray,
standardized and customized fluorescence in situ hybridization
(FISH) and high-resolution karyotyping. CombiMatrix is dedicated to
providing high-level clinical support for healthcare professionals
in order to help them incorporate the results of complex genetic
testing into patient-centered medical decision making. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling (800) 710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," “optimistic,” "continue," "ongoing," similar
expressions, and variations or negatives of these words and
include, but are not limited to, statements regarding projected
results of operations and management's future business, operational
and strategic plans, recruiting efforts and test menu expansion.
These forward-looking statements are not guarantees of future
results and are subject to risks, uncertainties and assumptions
that could cause our actual results to differ materially and
adversely from those expressed in any forward-looking statement.
The risks and uncertainties referred to above include, but are not
limited to: our ability to successfully market our PGS Multicycle
Program and other diagnostic test offerings, to successfully expand
the base of our customers and strategic partners, add to the menu
of our diagnostic tests, develop and introduce new tests and
related reports, expand and improve our current suite of services,
optimize the reimbursements received for our microarray testing
services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to
successfully accelerate sales, steadily increase the size of our
customer rosters in both prenatal and developmental genetic testing
markets; our ability to attract and retain a qualified sales
force in wider geographies; our ability to ramp production from our
sales force and our strategic partners; rapid technological change
in our markets; changes in demand for our future services;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further information
on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Relations Contact:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024